Generation and characterization of human iPSC line generated from mesenchymal stem cells derived from adipose tissue

Abstract In this work, mesenchymal stem cells derived from adipose tissue (ADSCs) were used for the generation of the human-induced pluripotent stem cell line G15.AO. Cell reprogramming was performed using retroviral vectors containing the Yamanaka factors, and the generated G15.AO hiPSC line showed normal karyotype, silencing of the exogenous reprogramming factors, induction of the typical pluripotency-associated markers, alkaline phosphatase enzymatic activity, and in vivo and in vitro differentiation ability to the three germ layers

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

CRISPR/Cas9 technology offers novel approaches for the development of new therapies for many unmet clinical needs, including a significant number of inherited monogenic diseases. However, in vivo correction of disease-causing genes is still inefficient, especially for those diseases without selective advantage for corrected cells. We reasoned that substrate reduction therapies (SRT) targeting non-essential enzymes could provide an attractive alternative. Here we evaluate the therapeutic efficacy of an in vivo CRISPR/Cas9-mediated SRT to treat primary hyperoxaluria type I (PH1), a rare inborn dysfunction in glyoxylate metabolism that results in excessive hepatic oxalate production causing end-stage renal disease. A single systemic administration of an AAV8-CRISPR/Cas9 vector targeting glycolate oxidase, prevents oxalate overproduction and kidney damage, with no signs of toxicity in Agxt1(-/-) mice. Our results reveal that CRISPR/Cas9-mediated SRT represents a promising therapeutic option for PH1 that can be potentially applied to other metabolic diseases caused by the accumulation of toxic metabolites

Identification and Characterization of pluripotency associated IncRNAs in human iPS cells

Induced pluripotent stem cells (iPSCs) are an attractive source of stem cells for many applications like patient-specific cell therapy, disease modeling or drug screening. Generation of iPSCs by cellular reprogramming is a complex and highly inefficient process that involves a high number of genetic and epigenetic modifications most of them unknown. Those genetic modifications include both coding and non-coding genes like long non-coding RNAs (lncRNAs). A detailed knowledge of the factors that make a cell to return to its own origin would help to a deeper understanding of the reprogramming process and to address new strategies that solve the current problems within this field. LncRNAs have been found to be involved in a wide variety of cellular processes, including embryonic development and cancer. Recently, some lncRNAs have been described as markers of the pluripotent state in addition to enhance the efficiency of somatic cells reprogramming. In order to further our knowledge in the reprogramming mechanisms mediated by lncRNAs, the expression profile of coding and non-coding genes was evaluated in fully characterized human iPSC clones generated from freshly isolated human fibroblasts and ADSCs by retroviral induction of POU5F1, SOX2, KLF4 and c-MYC. After the evaluation of differentially expressed lncRNAs between iPSCs derived from ADSCs and their parental cells 37 lncRNAs associated to the pluripotent state (PALs) were identified. Eleven of those PALs were fully characterized being all of them up-regulated in a considerable number of different pluripotent cells, a behavior characteristic of the un-differentiated stem cell state. Four out of the 11 PALs decrease their expression in both Fib-hiPSCs and ADSCs-hiPSCs submitted to differentiation cues. Finally, PAL20 and PAL21 were identified as the most robust candidates due to their high expression in all pluripotent stem cells analyzed and their dramatic and promptly depletion upon spontaneous differentiation. Gain of function and loss of function analysis confirmed that the induction of PAL20 and PAL21 expression is required for the establishment of ES-like colonies. On the other hand, silencing of those transcripts reduced the expression of specific pluripotent markers; lead to mild increase of specific lineage markers as well as a decrease on the proliferation rate of pluripotent cells

Identification and Characterization of pluripotency associated IncRNAs in human iPS cells

Induced pluripotent stem cells (iPSCs) are an attractive source of stem cells for many applications like patient-specific cell therapy, disease modeling or drug screening. Generation of iPSCs by cellular reprogramming is a complex and highly inefficient process that involves a high number of genetic and epigenetic modifications most of them unknown. Those genetic modifications include both coding and non-coding genes like long non-coding RNAs (lncRNAs). A detailed knowledge of the factors that make a cell to return to its own origin would help to a deeper understanding of the reprogramming process and to address new strategies that solve the current problems within this field. LncRNAs have been found to be involved in a wide variety of cellular processes, including embryonic development and cancer. Recently, some lncRNAs have been described as markers of the pluripotent state in addition to enhance the efficiency of somatic cells reprogramming. In order to further our knowledge in the reprogramming mechanisms mediated by lncRNAs, the expression profile of coding and non-coding genes was evaluated in fully characterized human iPSC clones generated from freshly isolated human fibroblasts and ADSCs by retroviral induction of POU5F1, SOX2, KLF4 and c-MYC. After the evaluation of differentially expressed lncRNAs between iPSCs derived from ADSCs and their parental cells 37 lncRNAs associated to the pluripotent state (PALs) were identified. Eleven of those PALs were fully characterized being all of them up-regulated in a considerable number of different pluripotent cells, a behavior characteristic of the un-differentiated stem cell state. Four out of the 11 PALs decrease their expression in both Fib-hiPSCs and ADSCs-hiPSCs submitted to differentiation cues. Finally, PAL20 and PAL21 were identified as the most robust candidates due to their high expression in all pluripotent stem cells analyzed and their dramatic and promptly depletion upon spontaneous differentiation. Gain of function and loss of function analysis confirmed that the induction of PAL20 and PAL21 expression is required for the establishment of ES-like colonies. On the other hand, silencing of those transcripts reduced the expression of specific pluripotent markers; lead to mild increase of specific lineage markers as well as a decrease on the proliferation rate of pluripotent cells

Generation and characterization of human iPSC line generated from mesenchymal stem cells derived from adipose tissue

Abstract In this work, mesenchymal stem cells derived from adipose tissue (ADSCs) were used for the generation of the human-induced pluripotent stem cell line G15.AO. Cell reprogramming was performed using retroviral vectors containing the Yamanaka factors, and the generated G15.AO hiPSC line showed normal karyotype, silencing of the exogenous reprogramming factors, induction of the typical pluripotency-associated markers, alkaline phosphatase enzymatic activity, and in vivo and in vitro differentiation ability to the three germ layers

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

CRISPR/Cas9 technology offers novel approaches for the development of new therapies for many unmet clinical needs, including a significant number of inherited monogenic diseases. However, in vivo correction of disease-causing genes is still inefficient, especially for those diseases without selective advantage for corrected cells. We reasoned that substrate reduction therapies (SRT) targeting non-essential enzymes could provide an attractive alternative. Here we evaluate the therapeutic efficacy of an in vivo CRISPR/Cas9-mediated SRT to treat primary hyperoxaluria type I (PH1), a rare inborn dysfunction in glyoxylate metabolism that results in excessive hepatic oxalate production causing end-stage renal disease. A single systemic administration of an AAV8-CRISPR/Cas9 vector targeting glycolate oxidase, prevents oxalate overproduction and kidney damage, with no signs of toxicity in Agxt1(-/-) mice. Our results reveal that CRISPR/Cas9-mediated SRT represents a promising therapeutic option for PH1 that can be potentially applied to other metabolic diseases caused by the accumulation of toxic metabolites